Dosage protocol · Metabolic & Weight Loss
Cagrilintide 5 mg
Typical weekly range: 0.6–4.5 mg once weekly (gradual titration over 4–6 weeks).
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Typical weekly range: 0.6–4.5 mg once weekly (gradual titration over 4–6 weeks).
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 0.0167 mg (16.7 mcg) on a U‑100 insulin syringe.
- Storage: Lyophilized: store frozen at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.
BAC water3.0mL
Concentration1.67mg/mL
Reconstitution
Cagrilintide dosage chart
Cagrilintide dosage chart
| Week | Week | Draw | Draw |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 36 units | 0.36 mL |
| Weeks 3–4 | 1.2 mg | 72 units | 0.72 mL |
| Weeks 5–6 | 2.4 mg | 144 units | 1.44 mL |
| Weeks 7–16 (Maintenance) | 4.5 mg | 270 units | 2.70 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
Cagrilintide is a long-acting synthetic analog of amylin, a hormone the pancreas releases alongside insulin to help regulate satiety and post-meal metabolism. Researchers modified native amylin's structure to resist the fibril formation that limits its natural stability, extending its duration of action enough for once-weekly dosing. Cagrilintide has been studied on its own, but it is best known as the amylin component of CagriSema, an investigational once-weekly combination with the GLP-1 receptor agonist semaglutide, both under development by Novo Nordisk for chronic weight management.
Benefits & side effects
The dominant safety signal across CagriSema trials has been gastrointestinal: nausea, constipation, and vomiting occurred in roughly 73-80% of CagriSema-treated participants across the two REDEFINE trials, versus about 34-40% on placebo, mostly described as transient and mild to moderate.[9][10] Because CagriSema combines cagrilintide with semaglutide, much of its established warning profile comes from semaglutide's own labeling rather than cagrilintide-specific data, including:
- Acute pancreatitis and gallbladder disease
- Hypoglycemia risk when used with insulin or other glucose-lowering medicines
- Kidney injury related to dehydration from vomiting or diarrhea
- Increased heart rate and, in people with type 2 diabetes, diabetic retinopathy complications
Cagrilintide-specific long-term safety, pregnancy, and drug-interaction data remain limited in the absence of a standalone approved label.[14]
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.
1
Reconstitution
mg
mL
Concentration—
Per unit (0.01 mL)—
Per 10 units (0.1 mL)—
2
Your dose
Doses per vial—
Vial lasts—
Draw to
— units
=
—
Other vial sizes
